Peter Greenberg

Clinical Focus

• Cancer > Hematology
• Hematology
• Myelodysplastic Syndromes

Administrative Appointments

• Director, Stanford MDS Center (1998 - 2008)
• Head, Hematology Section, VA Palo Alto Health Care System (1979 - 2005)
• Acting Chief, Medical Service, VA Palo Alto Health Care System (1978 - 1979)

Honors and Awards

• International Prize for outstanding research in myelodysplastic syndromes (MDS), J.P. McCarthy Foundation (1997)

Professional Education

Community & International Work

• Chair, Committee on International Outreach, 1998-2001 

Web Site Links

• http://hematology.stanford.edu/

Research Interests

The major direction of research in my laboratory is to determine the role and mechanisms of hemopoietic dysregulation in human myeloid malignancies. The relation between molecular changes and cellular phenotype / pathophysiology is being explored using microarray technology to evaluate differential gene expression profiles of MDS and AML marrow cells. The impact of cytokines and biologic response modifiers on these molecular features and hemopoietic response is being examined in clinical investigations with MDS and AML patients in therapeutic clinical trials with these agents.

Clinical Trials

• Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Recruiting
• Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) Recruiting
• Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Recruiting
• Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk Recruiting
• Study of 48-Hour Infusion of ON 01910.Na in Patients With MDS Recruiting

Publications

• A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL. Am J Hematol. 2009; 84 (1): 15-20
• Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Sridhar K, Ross DT, Tibshirani R, Butte AJ, Greenberg PL. Blood. 2009
• Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM. Blood. 2009; 114 (12): 2393-400
• Myelodysplastic syndromes. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P. J Natl Compr Canc Netw. 2008; 6 (9): 902-26
• Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. Sloand EM, Wu C, Greenberg P, et al. J Clin Oncol. 2008: 26 2505-2511